Shares of Xencor Inc (NASDAQ:XNCR) have received a consensus recommendation of “Buy” from the fourteen research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, nine have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $48.78.
XNCR has been the subject of a number of research analyst reports. Leerink Swann set a $52.00 price objective on Xencor and gave the stock a “buy” rating in a report on Wednesday, August 7th. ValuEngine upgraded Xencor from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 2nd. Guggenheim cut Xencor from a “buy” rating to a “neutral” rating in a report on Wednesday, August 7th. Wedbush boosted their price objective on Xencor from $43.00 to $54.00 and gave the stock an “outperform” rating in a report on Wednesday, August 7th. They noted that the move was a valuation call. Finally, Cantor Fitzgerald restated a “buy” rating and set a $40.00 price objective on shares of Xencor in a report on Sunday, May 12th.
In other Xencor news, major shareholder John S. Stafford III purchased 12,641 shares of the company’s stock in a transaction dated Thursday, June 6th. The stock was bought at an average cost of $29.87 per share, for a total transaction of $377,586.67. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 4.33% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada raised its holdings in shares of Xencor by 42.7% during the second quarter. Royal Bank of Canada now owns 2,004 shares of the biopharmaceutical company’s stock valued at $82,000 after purchasing an additional 600 shares during the period. Nuveen Asset Management LLC acquired a new position in shares of Xencor during the second quarter valued at about $11,073,000. Marshall Wace LLP raised its holdings in shares of Xencor by 1,320.1% during the second quarter. Marshall Wace LLP now owns 364,291 shares of the biopharmaceutical company’s stock valued at $14,910,000 after purchasing an additional 338,639 shares during the period. EcoR1 Capital LLC raised its holdings in shares of Xencor by 13.5% during the second quarter. EcoR1 Capital LLC now owns 2,336,557 shares of the biopharmaceutical company’s stock valued at $95,635,000 after purchasing an additional 277,128 shares during the period. Finally, Bank of America Corp DE raised its holdings in shares of Xencor by 20.7% during the second quarter. Bank of America Corp DE now owns 50,607 shares of the biopharmaceutical company’s stock valued at $2,072,000 after purchasing an additional 8,679 shares during the period. Institutional investors own 83.02% of the company’s stock.
Xencor stock traded down $0.15 during midday trading on Wednesday, reaching $40.58. 309,100 shares of the company’s stock were exchanged, compared to its average volume of 349,294. Xencor has a 52 week low of $27.75 and a 52 week high of $48.38. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.27 and a current ratio of 8.27. The firm has a market cap of $2.28 billion, a price-to-earnings ratio of -31.12 and a beta of 1.39. The stock’s 50-day simple moving average is $42.90 and its 200 day simple moving average is $35.24.
Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Xencor had a return on equity of 8.40% and a net margin of 28.46%. The business had revenue of $19.49 million during the quarter, compared to analysts’ expectations of $7.58 million. Research analysts forecast that Xencor will post 0.05 earnings per share for the current year.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Featured Story: When can a hold rating present a buying opportunity?
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.